ENTX Archives - BioTuesdays

Developments

Entera reports robust data for pipeline programs in HypoPT and obesity

Entera Bio (NASDAQ: ENTX) has reported preclinical data at ENDO 2026, the annual meeting of the Endocrine Society, for its pipeline programs—EB612 in hypoparathyroidism (HypoPT) and EB618 in obesity and metabolic...

June 16, 2026

Developments

Entera reports positive data for oral GLP-2 tablet for SBS at 2025 ESPEN Congress

Entera Bio (NASDAQ: ENTX) has announced the presentation of a poster highlighting pharmacokinetic data relating to its first-in-class oral GLP-2 analog program for the treatment of short bowel syndrome (SBS), at the...

September 16, 2025

Feature

Entera Bio’s EB613 Oral PTH(1-34) Tablets Poised to Revolutionize Osteoporosis Care for 200 Million Post-Menopausal Women Globally

Entera Bio (NASDAQ:ENTX) is leveraging a disruptive technology platform called N-Tab to develop first-in-class, once-daily oral tablets of peptides and small therapeutic protein replacement therapies. The company...

August 20, 2024

Markets

Maxim doubles Entera Bio PT to $10 from $5 on new data; shares soar

Maxim Group raised its price target for Entera Bio (NASDAQ:ENTX) to $10 from $5, citing updated data from an ongoing Phase 2 trial of oral parathyroid hormone candidate, EB613, in osteoporosis. At midday on March 11...

March 11, 2021

Developments

Entera Bio completes enrollment in Phase 2 osteoporosis trial

Entera Bio (NASDAQ:ENTX) completed enrollment in its Phase 2 trial evaluating EB613 for the treatment of osteoporosis. EB613 is an orally delivered human parathyroid hormone designed to build bone in osteoporosis...

November 9, 2020

Developments

Entera Bio reports interim data from Phase 2 osteoporosis trial

Entera Bio (NASDAQ:ENTX) reported interim results from its Phase 2 trial assessing EB613 for the treatment of osteoporosis. The trial has currently enrolled 131 postmenopausal female subjects with osteoporosis, or low...

August 20, 2020

Tag - ENTX

Entera reports robust data for pipeline programs in HypoPT and obesity

Entera reports positive data for oral GLP-2 tablet for SBS at 2025 ESPEN Congress

Entera Bio’s EB613 Oral PTH(1-34) Tablets Poised to Revolutionize Osteoporosis Care for 200 Million Post-Menopausal Women Globally

Maxim doubles Entera Bio PT to $10 from $5 on new data; shares soar

Entera Bio completes enrollment in Phase 2 osteoporosis trial

Entera Bio reports interim data from Phase 2 osteoporosis trial

Subscribe